Right Heart Assessment in Cancer Patients: Call to Action
Echocardiography · 2025-06 · 42 (6)
DOI: 10.1111/echo.70212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Echocardiography, online erschienen am 04.06.2025. Verfasst von Sivatharshini Ramalingam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cardio-Oncology Centre of Excellence, Royal Brompton Hospital, London, UK. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Classical and modern anticancer therapies have significantly improved the prognosis of cancer patients, but this progress comes with the cost of increased rate of cardiovascular (CV) toxicities.These therapies, while targeted at malignant cells, exert systemic effects that extend far beyond the tumor microenvironment, profoundly impacting the CV system.Chemotherapeutic agents, radiation, and immunotherapies can induce a cascade of physiological changes, including inflammation, oxidative stress, and direct cellular toxicity.Furthermore, cancer is considered a systemic disease, even if not in advanced stage and it affects cardiac function.Inflammation that has a central role in cancer pathogenesis, induces cachexia and cardiac wasting [1].Systemic metabolic alterations related to cancer lead to myocardial dysfunction and heart failure [2].While cardio-oncology guidelines and the definition of cancer therapeutics-related cardiac dysfunction (CTRCD) by the Heart Failure Association (HFA) and the International Cardio-Oncology Society (ICOS), as well as the Common Terminology Criteria for Adverse Events (CTCAE) used in oncology trials primarily focus on the left ventricle (LV) [3,4], a growing body of research reveals the impact of cancer and anticancer treatments on the right ventricle (RV) as well [5,6], with potential impact on patients' outcome.This aligns with the critical role of RV structural and functional impairment in several CV and other systemic diseases.Typical CV entities in which RV dysfunction has a pivotal role in clinical presentation, trajectory and prognosis include chronic and acute LV failure [7,8], pulmonary hypertension, congenital heart diseases like atrial septal defect, tetralogy of Fallot, Ebstein anomaly, RV outflow obstruction [9], valvular diseases like mitral and aortic stenosis and several "left-sided" cardiomyopathies (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy and restrictive cardiomyopathies, i.e., cardiac amyloidosis and cardiac
Autor:innen und Institutionen
- Cardio-Oncology Centre of Excellence, Royal Brompton Hospital, London, UK.
- Oxted Health Centre, Oxted, Surrey, England.
- Department of Cardiology, Hospital da Luz, Lisbon, Portugal.
- NOVA Medical School, Lisbon, Portugal.
- Echocardiography department, Interbalkan Medical Center, Thessaloniki, Greece.
- Department of Cardiology, General Anticancer Oncological Hospital Agios Savvas, Athens, Greece.
ORCID-Profile: Konstantinos Papadopoulos, Kalliopi Keramida
Zitieren
APA
Ramalingam, S., Toste, J., Papadopoulos, K., & Keramida, K. (2025). Right Heart Assessment in Cancer Patients: Call to Action. Echocardiography, 42(6). https://doi.org/10.1111/echo.70212
Vancouver
Ramalingam S, Toste J, Papadopoulos K, Keramida K. Right Heart Assessment in Cancer Patients: Call to Action. Echocardiography. 2025;42(6). doi:10.1111/echo.70212
BibTeX
@article{Ramalingam2025,
author = {Ramalingam, Sivatharshini and Toste, Julia and Papadopoulos, Konstantinos and Keramida, Kalliopi},
title = {Right Heart Assessment in Cancer Patients: Call to Action},
journal = {Echocardiography},
year = {2025},
volume = {42},
number = {6},
doi = {10.1111/echo.70212}
}
EUVIMED